fda glp-1 warning 2025 november letters warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain Data Integrity : Key Lessons – FDA cracks down on 'misleading'

Some doctors prescribed Ozempic or other GLP-1 drugs off-label for weight loss to non-diabetic patients or even pediatric patients, without FDA approval and without giving adequate warnings about the risks

doi: 10.1101/cshperspect.a026104 10 ChoH

When combining with sermorelin for systemic effects, subcutaneous injection is generally preferred because topical bioavailability through intact skin is limited, estimated at below 30% in most penetration studies

These findings indicate that BPC 157 exerts its pro-angiogenic effects by increasing VEGFR2 expression and promoting its internalization and subsequent activation of the VEGFR2-Akt-eNOS signaling cascade

The new oral formulation delivers weight loss results comparable to its injectable counterpart in clinical studies

Those with G6PD deficiency should approach with caution